Literature DB >> 25611102

Clinical validation of targeted next-generation sequencing for inherited disorders.

Sophia Yohe1, Adam Hauge, Kari Bunjer, Teresa Kemmer, Matthew Bower, Matthew Schomaker, Getiria Onsongo, Jon Wilson, Jesse Erdmann, Yi Zhou, Archana Deshpande, Michael D Spears, Kenneth Beckman, Kevin A T Silverstein, Bharat Thyagarajan.   

Abstract

CONTEXT: Although next-generation sequencing (NGS) can revolutionize molecular diagnostics, several hurdles remain in the implementation of this technology in clinical laboratories.
OBJECTIVES: To validate and implement an NGS panel for genetic diagnosis of more than 100 inherited diseases, such as neurologic conditions, congenital hearing loss and eye disorders, developmental disorders, nonmalignant diseases treated by hematopoietic cell transplantation, familial cancers, connective tissue disorders, metabolic disorders, disorders of sexual development, and cardiac disorders. The diagnostic gene panels ranged from 1 to 54 genes with most of panels containing 10 genes or fewer.
DESIGN: We used a liquid hybridization-based, target-enrichment strategy to enrich 10 067 exons in 568 genes, followed by NGS with a HiSeq 2000 sequencing system (Illumina, San Diego, California).
RESULTS: We successfully sequenced 97.6% (9825 of 10 067) of the targeted exons to obtain a minimum coverage of 20× at all bases. We demonstrated 100% concordance in detecting 19 pathogenic single-nucleotide variations and 11 pathogenic insertion-deletion mutations ranging in size from 1 to 18 base pairs across 18 samples that were previously characterized by Sanger sequencing. Using 4 pairs of blinded, duplicate samples, we demonstrated a high degree of concordance (>99%) among the blinded, duplicate pairs.
CONCLUSIONS: We have successfully demonstrated the feasibility of using the NGS platform to multiplex genetic tests for several rare diseases and the use of cloud computing for bioinformatics analysis as a relatively low-cost solution for implementing NGS in clinical laboratories.

Entities:  

Mesh:

Year:  2015        PMID: 25611102     DOI: 10.5858/arpa.2013-0625-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  22 in total

1.  Insurance companies are slow to cover next-generation sequencing.

Authors:  Shraddha Chakradhar
Journal:  Nat Med       Date:  2015-03       Impact factor: 53.440

2.  Determination of IDH1, IDH2, MGMT, TERT and ATRX Gene Mutations in Glial Tumors.

Authors:  Cumhur Kaan Yaltirik; Seda Gulec Yilmaz; Selcuk Ozdogan; Ezel Yaltirik Bilgin; Zerrin Barut; Ugur Ture; Turgay Isbir
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

3.  Targeted Next-Generation Sequencing for Clinical Diagnosis of 561 Mendelian Diseases.

Authors:  Yanqiu Liu; Xiaoming Wei; Xiangdong Kong; Xueqin Guo; Yan Sun; Jianfen Man; Lique Du; Hui Zhu; Zelan Qu; Ping Tian; Bing Mao; Yun Yang
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

4.  Implementation of Cloud based next generation sequencing data analysis in a clinical laboratory.

Authors:  Getiria Onsongo; Jesse Erdmann; Michael D Spears; John Chilton; Kenneth B Beckman; Adam Hauge; Sophia Yohe; Matthew Schomaker; Matthew Bower; Kevin A T Silverstein; Bharat Thyagarajan
Journal:  BMC Res Notes       Date:  2014-05-23

5.  Targeted Next Generation Sequencing in Patients with Inborn Errors of Metabolism.

Authors:  Dèlia Yubero; Núria Brandi; Aida Ormazabal; Àngels Garcia-Cazorla; Belén Pérez-Dueñas; Jaime Campistol; Antonia Ribes; Francesc Palau; Rafael Artuch; Judith Armstrong
Journal:  PLoS One       Date:  2016-05-31       Impact factor: 3.240

6.  Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes.

Authors:  Emma S Reid; Apostolos Papandreou; Suzanne Drury; Christopher Boustred; Wyatt W Yue; Yehani Wedatilake; Clare Beesley; Thomas S Jacques; Glenn Anderson; Lara Abulhoul; Alex Broomfield; Maureen Cleary; Stephanie Grunewald; Sophia M Varadkar; Nick Lench; Shamima Rahman; Paul Gissen; Peter T Clayton; Philippa B Mills
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

Review 7.  Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations.

Authors:  Abdellah Tebani; Carlos Afonso; Stéphane Marret; Soumeya Bekri
Journal:  Int J Mol Sci       Date:  2016-09-14       Impact factor: 5.923

8.  Targeted Enrichment for Pathogen Detection and Characterization in Three Felid Species.

Authors:  Justin S Lee; Ryan S Mackie; Thomas Harrison; Basir Shariat; Trey Kind; Timo Kehl; Martin Löchelt; Christina Boucher; Sue VandeWoude
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

9.  Next-generation sequencing using a pre-designed gene panel for the molecular diagnosis of congenital disorders in pediatric patients.

Authors:  Eileen C P Lim; Maggie Brett; Angeline H M Lai; Siew-Peng Lee; Ee-Shien Tan; Saumya S Jamuar; Ivy S L Ng; Ene-Choo Tan
Journal:  Hum Genomics       Date:  2015-12-14       Impact factor: 4.639

10.  Prevalence of Rare Genetic Variations and Their Implications in NGS-data Interpretation.

Authors:  Yangrae Cho; Chul-Ho Lee; Eun-Goo Jeong; Min-Ho Kim; Jong Hui Hong; Younhee Ko; Bomnun Lee; Gilly Yun; Byong Joon Kim; Jongcheol Jung; Jongsun Jung; Jin-Sung Lee
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.